BIIB022 / Biogen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BIIB022 / Biogen
NCT00956436: Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Completed
1b
40
US, Europe, RoW
BIIB022, IGF-1R, Liver Cancer, Hepatocellular Carcinoma, Monoclonal Antibody, Sorafenib, HCC, Nexavar
Biogen
Hepatocellular Carcinoma
04/11
04/11
NCT00970580: A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Completed
1b
18
US
BIIB022 With Paclitaxel and Carboplatin, Taxol, Paraplatin, BIIB022, Taxane, Anti-IGF-1R, Cytotoxic, Mitotic Inhibitor, IGF-1R, Alkylating agent
Biogen
Non-Small Cell Lung Cancer
09/11
09/11
NCT00555724: Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Completed
1
40
US
BIIB022, IGF-1R
Biogen
Solid Tumors
04/10
07/10

Download Options